Table 1 Markers of bone turnover and calcium homeostasis during r-hPRL or placebo treatment

Before treatment

After treatment

Before treatment

After treatment

Deoxypyridinoline (nM/mM)

7.2 ± 0.6

6.9 ± 0.7

9.5 ± 2.1

7.4 ± 1.8

N-telopeptide (nM/mM Cr)

45.3 ± 4.6

42.3 ± 5.6

35.6 ± 4.0

31.9 ± 4.1

Bone specific alk phos (U/L)

15.4 ± 1.3

17.5 ± 1.5*

17.0 ± 2.2

18.1 ± 2.5

Calcium (mmol/L)

2.3 ± 0.03

2.4 ± 0.03*

2.3 ± 0.03

2.4 ± 0.03*

Albumin (g/L)

40 ± 1

43 ± 1*

40 ± 1

42 ± 1

Corrected calcium (mmol/L)

2.4 ± 0.03

2.4 ± 0.03

2.4 ± 0.03

2.5 ± 0.05

Phosphorus (mmol/L)

1.2 ± 0.03

1.1 ± 0.03

1.0 ± 0.06

1.1 ± 0.06

PTH (ng/L)

45.7 ± 4.4

47.6 ± 4.5

46.8 ± 5.9

38.8 ± 6.2

PTH-rP (pmol/L)

0.33 ± 0.02

0.35 ± 0.04

0.30 ± 0.00

0.37 ± 0.05

1,25-(OH) ₂ Vit D (pmol/L)

102.2 ± 7.0

102.2 ± 6.7

115.4 ± 17.5

117.6 ± 25.2

Urinary Ca/Cr

0.11 ± 0.02

0.11 ± 0.02

0.10 ± 0.02

0.15 ± 0.02

Urinary Phos/Cr

0.61 ± 0.07

0.61 ± 0.08

0.60 ± 0.07

0.59 ± 0.05